Gyrodyne LLC（GYRO）股票分析

AI 分析 of Gyrodyne LLC (GYRO)

持有

Gyrodyne LLC (GYRO) is currently trading at $4.00, which is significantly below its 52-week high of $9.71, indicating potential for recovery. However, the stock has seen a year-to-date decline of 55.85% and a 20-day change of -15.07%, suggesting ongoing weakness. The RSI is extremely low at 8.117, indicating the stock is oversold, but this could also reflect deeper issues. The forward P/E ratio is 0, indicating no earnings expectations, which is a red flag. Given these factors, while there is potential upside, the significant risks outweigh the current buying opportunity, making it prudent to hold rather than buy.

估值指標

Gyrodyne LLC（GYRO）目前預期本益比為 0.00，5 年平均預期本益比為 0.00。

預期本益比

嚴重低估

5 年均值 P/E

0.00

目前P/E

0.00

高估

0.00

低估

0.00

預期 EV/EBITDA

嚴重低估

5 年均值 EV/EBITDA

0.00

目前EV/EBITDA

0.00

高估

0.00

低估

0.00

預期股價營收比

合理

5 年均值 P/S

0.12

目前P/S

0.00

高估

1.17

低估

-0.94

Alphio AI 對 GYRO 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%GYRO

$9.32

情境價格

基

基準

基準 · 50%GYRO

$7.82

情境價格

悲

悲觀

悲觀 · 25%GYRO

$6.16

情境價格

GYRO 常見問題 —— 由 Alphio AI 解答

Gyrodyne, LLC owns and manages diverse commercial properties. The Company’s primary business is the management of a portfolio of medical office and industrial properties and the pursuit of entitlements on such properties located in Suffolk (Flowerfield) and Westchester (Cortlandt Manor) Counties, New York. The Company owns about a 63-acre site approximately 50 miles east of New York City on the north shore of Long Island, which includes industrial and office buildings and undeveloped property, and a medical office park in Cortlandt Manor, New York. In Cortlandt Manor, New York, the Company owns about 13.8 acres inclusive of the 31,421-square-foot Cortlandt Medical Center. It operates in the Real Estate sector (OPERATORS OF NONRESIDENTIAL BUILDINGS industry).

Gyrodyne LLC (GYRO) is currently trading at $4.00, which is significantly below its 52-week high of $9.71, indicating potential for recovery. However, the stock has seen a year-to-date decline of 55.85% and a 20-day change of -15.07%, suggesting ongoing weakness. The RSI is extremely low at 8.117, indicating the stock is oversold, but this could also reflect deeper issues. The forward P/E ratio is 0, indicating no earnings expectations, which is a red flag. Given these factors, while there is potential upside, the significant risks outweigh the current buying opportunity, making it prudent to hold rather than buy.